Lenalidomide following rituximab and fludarabine in untreated CLL.
Chaitra S. Ujjani(Fred Hutch Cancer Center), Bruce D. Cheson(Center for Cancer and Blood Disorders), Craig M. Kessler(Georgetown University), Saad Jamshed(Unity Health System), Kelly Fitzpatrick(Blanchfield Army Community Hospital), Pascale A. Cohen(Lyon 1 Université), J. Crawford, E. A. Gehan(The University of Texas MD Anderson Cancer Center), Catherine M. Broome(Georgetown University)
Cited by 4
Related Papers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
|Journal of Clinical Oncology|2014|1.6k